Corcept Therapeutics (NASDAQ:CORT) Upgraded to Strong-Buy at StockNews.com

StockNews.com upgraded shares of Corcept Therapeutics (NASDAQ:CORT – Free Report) from a buy rating to a strong-buy rating in a research note published on Thursday morning. A number of other analysts also recently issued reports on CORT. Canaccord Genuity Group increased their price target on shares of Corcept Therapeutics from $34.00 to $35.00 and gave […]

Leave a Reply

Your email address will not be published.

Previous post Avis Budget Group (NASDAQ:CAR) Upgraded by StockNews.com to Hold
Next post John Martin Fischer: Some scientists say we don’t have free will. As a philosopher I say, of course we do